OUR PRODUCT
MyProstateScore 2.0
Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.
Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.
MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for providers and both biopsy naïve and prior negative patients.
You deserve the next generation in prostate cancer risk prediction for men’s health.
How It Works
Our Science. Clear Results. Your Decision.
A simple urine test that shines a highly sensitive light on a patient’s actual risk of prostate cancer when PSA is elevated. Our data models have combined those clinical factors most relevant for both biopsy naïve and prior negative patient populations. Our goal is to provide a solution with zero surprises for all involved.
MPS2
Early Prostate Cancer Risk Assessment
One in eight men will receive a prostate cancer diagnosis during their lifetime. The good news? Survival is nearly 100% when diagnosed early and contained within the prostate. When it spreads, however, the five-year survival is just 31%.
Early detection is critical for you and your family.
You can avoid subjective, invasive tests and receive a highly accurate prostate cancer screening to assess your current risk.
MyProstateScore 2.0 can give you and your urologist accurate data to make a personalized healthcare decision for you.
Stay Up-To-Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
A Brief Glossary of Terms Related to Prostate Cancer
Prostate cancer awareness is key for men’s health. Get comfortable with terms like “biopsy,” “PSA,” “clinically significant” and “grade group.”
The Importance of Community Outreach and Involvement in Black Men’s Fight Against Prostate Cancer
A community-based approach to educating Black men about prostate cancer and increasing access to care can help close the health disparity gap.
Determining Prostate Cancer Risk When a Prostate Biopsy is Negative
Men who’ve had a negative prostate biopsy and still have high PSA are a unique group. Biomarker screening could help these patients avoid a repeat biopsy.